Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines

A promising personal immunotherapy is autologous dendritic cells (DC) loaded ex vivo with autologous tumor antigens (ATA) derived from self-renewing autologous cancer cells. DC-ATA are suspended in granulocyte-macrophage colony stimulating factor at the time of each subcutaneous injection. Previousl...

Full description

Bibliographic Details
Main Authors:	Robert O. Dillman, Gabriel I. Nistor, Hans S. Keirstead
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-01-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	dendritic cells autologous tumor antigens cancer stem cells tumor initiating cells cancer vaccine personalized immunotherapy personal immunotherapy
Online Access:	http://dx.doi.org/10.1080/21645515.2023.2198467

Similar Items

Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads
by: Adela Kiessling, et al.
Published: (2022-03-01)

Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
by: Robert Owen Dillman, et al.
Published: (2019-10-01)

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
by: Robert O Dillman, et al.
Published: (2019-06-01)

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
by: Robert O. Dillman, et al.
Published: (2018-03-01)

CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro
by: Farid Ghorbaninezhad, et al.
Published: (2022-08-01)

EFFECT OF ANTIGEN-PRIMED DENDRITIC CELL-BASED IMMUNOTHERAPY ON ANTITUMOR CELLULAR IMMUNE RESPONSE IN PATIENTS WITH COLORECTAL CANCER
by: V. V. Kurilin, et al.
Published: (2021-10-01)

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
by: Daniela A. Bota, et al.
Published: (2022-12-01)

Editorial: Dendritic cell-primed T cells in anti-tumor immune responses and relevant vaccine strategies
by: Jianmei W. Leavenworth, et al.
Published: (2022-09-01)

Editorial: Novel Platform for Antigen Delivery to Dendritic Cells for Immunotherapy
by: Maud Plantinga, et al.
Published: (2022-05-01)

The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment
by: Anna Valerevna Gorodilova, et al.
Published: (2023-10-01)

Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases
by: Vasily Kurilin, et al.
Published: (2024-03-01)

The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
by: Elena V. Abakushina, et al.
Published: (2021-11-01)

In Situ Dendritic Cell Recruitment and T Cell Activation for Cancer Immunotherapy
by: Joonsu Han, et al.
Published: (2022-08-01)

Dendritic Cell-Based Immunotherapy in Lung Cancer
by: Dieter Stevens, et al.
Published: (2021-02-01)

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
by: Chia-Ing Jan, et al.
Published: (2018-05-01)

Tumor mRNA-Transfected Dendritic Cells Stimulate the Generation of CTL That Recognize Neuroblastoma-Associated Antigens, Kill Tumor Cells: Immunotherapeutic Implications
by: Fabio Morandi, et al.
Published: (2006-10-01)

An in vitro investigation into the cytotoxic impact of antigen-presenting dendritic cell-tumor infiltrating lymphocytes on ovarian cancer cells
by: Shengnan Yang, et al.
Published: (2024-11-01)

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
by: Michal Bassani-Sternberg, et al.
Published: (2019-08-01)

Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer
by: Enrica Marmonti, et al.
Published: (2022-09-01)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
by: Simone A. Minnie, et al.
Published: (2021-03-01)

Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
by: Heng Dong, et al.
Published: (2023-06-01)

Dendritic Cell Vaccines in Ovarian Cancer
by: Xi Zhang, et al.
Published: (2021-01-01)

Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results
by: Beatris Mastelic-Gavillet, et al.
Published: (2019-04-01)

Targeting dendritic cells in pancreatic ductal adenocarcinoma
by: Anton Deicher, et al.
Published: (2018-06-01)

Dendritic cell-targeting chemokines inhibit colorectal cancer progression
by: Pengkun Yuan, et al.
Published: (2022-12-01)

Autologous Dendritic Cell Vaccine Optimization for Therapy of Patients with Disseminated Malignant Ne
by: T. L. Nehaeva
Published: (2016-02-01)

Dendritic Cell-targeted approaches to modulate immune dysfunction in the Tumor Microenvironment
by: Anne eGallois, et al.
Published: (2013-12-01)

Recent Advances in Experimental Dendritic Cell Vaccines for Cancer
by: Ivan Y. Filin, et al.
Published: (2021-09-01)

Efficient Predictor for Immunotherapy Efficacy: Detecting Pan‐Clones Effector Tumor Antigen‐Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens
by: Weibiao Zeng, et al.
Published: (2025-01-01)

Current state and prospects of using dendritic cell vaccination for cancer immunotherapy
by: I.Yu. Filin, et al.
Published: (2022-09-01)

New treatment modalities with vaccine therapy in renal cell carcinoma
by: Mehmet Giray Sonmez, et al.
Published: (2019-01-01)

Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets
by: Graziela Gorete Romagnoli, et al.
Published: (2015-01-01)

Dual Adjuvant‐Loaded Peptide Antigen Self‐Assembly Potentiates Dendritic Cell‐Mediated Tumor Immunotherapy
by: Jaehyun Kim, et al.
Published: (2024-09-01)

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
by: Linda M. Liau, et al.
Published: (2018-05-01)

Immunogenicity of Tumor Initiating Stem Cells: Potential Applications in Novel Anticancer Therapy
by: Durga Khandekar, et al.
Published: (2019-04-01)

Dendritic Cell-Derived Exosomes in Cancer Immunotherapy
by: Shumin Luo, et al.
Published: (2023-08-01)

Dendritic cell biology and its role in tumor immunotherapy
by: Yingying Wang, et al.
Published: (2020-08-01)

Dendritic Cell Therapies for Hematologic Malignancies
by: Matthew Weinstock, et al.
Published: (2017-06-01)

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
by: Kristian M. Hargadon
Published: (2017-11-01)

Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
by: Sarah I. M. Sutherland, et al.
Published: (2021-03-01)